These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 27624572)

  • 1. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis.
    Zusman O; Altunin S; Koppel F; Dishon Benattar Y; Gedik H; Paul M
    J Antimicrob Chemother; 2017 Jan; 72(1):29-39. PubMed ID: 27624572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
    Scudeller L; Righi E; Chiamenti M; Bragantini D; Menchinelli G; Cattaneo P; Giske CG; Lodise T; Sanguinetti M; Piddock LJV; Franceschi F; Ellis S; Carrara E; Savoldi A; Tacconelli E
    Int J Antimicrob Agents; 2021 May; 57(5):106344. PubMed ID: 33857539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
    Ardebili A; Izanloo A; Rastegar M
    Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymyxin Monotherapy vs. Combination Therapy for the Treatment of Multidrug-resistant Infections: A Systematic Review and Meta-analysis.
    Samal S; Samir SB; Patra SK; Rath A; Dash A; Nayak B; Mohanty D
    Indian J Crit Care Med; 2021 Feb; 25(2):199-206. PubMed ID: 33707900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
    Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
    Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy for carbapenem-resistant Gram-negative bacteria.
    Paul M; Carmeli Y; Durante-Mangoni E; Mouton JW; Tacconelli E; Theuretzbacher U; Mussini C; Leibovici L
    J Antimicrob Chemother; 2014 Sep; 69(9):2305-9. PubMed ID: 24872346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymyxin monotherapy versus polymyxin-based combination therapy against carbapenem-resistant Klebsiella pneumoniae: A systematic review and meta-analysis.
    Hou SY; Wu D; Feng XH
    J Glob Antimicrob Resist; 2020 Dec; 23():197-202. PubMed ID: 33091620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of Polymyxin Use in Patients.
    Paul M; Zusman O; Leibovici L
    Adv Exp Med Biol; 2019; 1145():143-153. PubMed ID: 31364077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.
    Crusio R; Rao S; Changawala N; Paul V; Tiu C; van Ginkel J; Chapnick E; Kupfer Y
    Scand J Infect Dis; 2014 Jan; 46(1):1-8. PubMed ID: 24206450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals.
    Papst L; Beović B; Pulcini C; Durante-Mangoni E; Rodríguez-Baño J; Kaye KS; Daikos GL; Raka L; Paul M;
    Clin Microbiol Infect; 2018 Oct; 24(10):1070-1076. PubMed ID: 29410094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections.
    Cai B; Cai Y; Liew YX; Chua NG; Teo JQ; Lim TP; Kurup A; Ee PL; Tan TT; Lee W; Kwa AL
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4013-22. PubMed ID: 27090177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis.
    Lyu C; Zhang Y; Liu X; Wu J; Zhang J
    BMC Infect Dis; 2020 Apr; 20(1):296. PubMed ID: 32316926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis.
    Ni W; Cai X; Wei C; Di X; Cui J; Wang R; Liu Y
    Braz J Infect Dis; 2015; 19(2):170-80. PubMed ID: 25636193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic combinations of polymyxins.
    Lenhard JR; Nation RL; Tsuji BT
    Int J Antimicrob Agents; 2016 Dec; 48(6):607-613. PubMed ID: 27865626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous Colistin Monotherapy versus Combination Therapy against Carbapenem-Resistant Gram-Negative Bacteria Infections: Meta-Analysis of Randomized Controlled Trials.
    Cheng IL; Chen YH; Lai CC; Tang HJ
    J Clin Med; 2018 Aug; 7(8):. PubMed ID: 30103414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colistin monotherapy or combination for the treatment of bloodstream infection caused by Klebsiella pneumoniae: a systematic review and meta-analysis.
    Wang T; Liu H; Huang H; Weng Y; Wang X
    BMC Infect Dis; 2024 Feb; 24(1):161. PubMed ID: 38317132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review.
    Jacobs DM; Safir MC; Huang D; Minhaj F; Parker A; Rao GG
    Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):76. PubMed ID: 29178957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of different polymyxin-containing regimens for the treatment of pneumonia caused by multidrug-resistant gram-negative bacteria: a systematic review and network meta-analysis.
    Zhou Y; Wang G; Zhao Y; Chen W; Chen X; Qiu Y; Liu Y; Wu S; Guan J; Chang P; Liu Y; Liu Z
    Crit Care; 2024 Jul; 28(1):239. PubMed ID: 39004760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study.
    Zak-Doron Y; Dishon Benattar Y; Pfeffer I; Daikos GL; Skiada A; Antoniadou A; Durante-Mangoni E; Andini R; Cavezza G; Leibovici L; Yahav D; Eliakim-Raz N; Carmeli Y; Nutman A; Paul M;
    Clin Infect Dis; 2018 Nov; 67(12):1815-1823. PubMed ID: 29718143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.